More than 10,000 patients with previous myocardial infarction and CRP levels > 2 mg/L, were randomized to receive placebo or three different subcutaneous doses of canakinumab every 3 months (50 mg, 150 mg, and 300 mg). This evidence concerns the gene CRP and myocardial infarction.